Although STING agonists have shown promising results for glioma treatment, most of them are usually administered through the intra-tumoral route due to their systemic toxicity and poor pharmacokinetic and physicochemical properties, which significantly limit their potential for clinical translation [37,62]. This evidence concerns the gene STING1 and glioma.